PLX Stock Risk & Deep Value Analysis
Protalix Biotherapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PLX Stock
We analyzed Protalix Biotherapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PLX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PLX Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is the concentrated revenue stream from Elfabrio and its reliance on the Chiesi partnership. If Elfabrio's commercial ramp-up globally significantly underperforms the 2026 revenue guidance ($78M-$83M, which includes a $25M milestone), or if Chiesi encounters unforeseen distribution or competitive challenges, Protalix's recently achieved profitability could reverse, leading to renewed cash burn from its Q1 2026 cash position of $51.1M.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
High revenue concentration: The majority of current and projected revenue for 2026 ($78M-$83M) is tied to Elfabrio sales and milestone payments from Chiesi.
- ⚠
Single-product reliance: While the ProCellEx platform offers long-term potential, the company's near-to-medium-term success is heavily dependent on one commercialized product, Elfabrio.
- ⚠
Historical cash burn: Although Q1 2026 marked a significant profitability turnaround, the company has a history of cash burn, which could resurface if sales falter.
Upcoming Risk Events
- 📅
Q2 2026 Earnings (Est. late July/early Aug 2026): Elfabrio product revenue (excluding milestone payments) falls below $15M, signaling commercialization struggles.
- 📅
Regulatory setback for Elfabrio (H2 2026): Major market regulator issues post-marketing requirement or safety flag, impacting market access or uptake.
When to Reconsider
- 🚪
Exit if quarterly product revenue (excluding milestone payments) drops below $15M for two consecutive quarters, indicating a failure to sustain growth.
- 🚪
Sell if cash balance drops below $20M (from $51.1M in Q1 2026) without a clear, non-dilutive funding path.
Unlock PLX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Protalix Biotherapeutics Inc (PLX) Do?
Market Cap
$161.55M
Sector
Healthcare
Industry
Biotechnology
Employees
213
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Visit Protalix Biotherapeutics Inc WebsiteInvestment Thesis
If Protalix, through its partnership with Chiesi, successfully ramps up global sales of Elfabrio to capture a significant share of the Fabry disease market, driving annual product revenue (excluding milestones) to $100M+ by FY2027 and sustaining the profitability demonstrated in Q1 2026, then the company could achieve a market cap re-rating to $1B+ (10x current market cap) within 3-5 years, representing a 10x return on investment, as the market discounts the current valuation due to historical losses and single-product reliance.
Is PLX Stock Undervalued?
Unlock the full AI analysis for PLX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PLX Price Targets & Strategy
12-Month Target
$11.00
Bull Case
$15.00
Bear Case
$3.00
Valuation Basis
Based on 12.5x forward P/E applied to estimated FY2026 EPS of $0.88 (derived from Q1 2026 EPS of $0.22 as a run-rate, plus potential for operational leverage and additional milestone payments within the $78M-$83M revenue guidance) – aligning with analyst consensus.
Entry Strategy
Dollar-cost average between $1.70-$2.00, near current levels and potential support zones, capitalizing on the market's current low P/E valuation relative to recent profitability.
Exit Strategy
Take 50% profit at $8.00 (midpoint of analyst target range), with a stop-loss at $1.50 if cash burn re-emerges or Elfabrio sales significantly underperform.
Portfolio Allocation
5% for aggressive risk tolerance
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is PLX Financially Healthy?
Valuation
P/E Ratio
10.54
Forward P/E
19.00
EV/EBITDA
13.31
PEG Ratio
7.85
Price/Book
2.94
Price/Sales
2.79
Profitability
Gross Margin
69.97%
Operating Margin
25.91%
Net Margin
20.07%
Return on Equity
28.10%
Revenue Growth
27.80%
EPS
$0.18
Balance Sheet
Current Ratio
2.51
Quick Ratio
1.53
Other
Beta (Volatility)
0.06
Does PLX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is protected by intellectual property for the ProCellEx platform and Elfabrio, along with regulatory exclusivity periods. The Chiesi partnership also enhances commercial durability. However, it faces competition from established therapies and the potential for new entrants.
Moat Erosion Risks
- •Patent expiry for Elfabrio or core ProCellEx technologies, allowing for generic competition.
- •Emergence of a superior Fabry disease therapy (e.g., gene therapy) that negates Elfabrio's advantages.
- •Manufacturing or supply chain issues impacting Elfabrio production via the ProCellEx system.
PLX Competitive Moat Analysis
Sign up to see competitive advantages
PLX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, with growing interest following Q1 profitability.
Institutional Sentiment
Positive, indicated by an average analyst price target of $11.00, suggesting strong conviction in the company's turnaround and Elfabrio's market potential.
Insider Activity (Form 4)
No specific Form 4 data provided in research; assuming neutral activity.
Options Flow
Normal options activity; no unusual volumes or directional biases noted in the provided research.
Earnings Intelligence
Next Earnings
Estimated late July/early August 2026 (for Q2 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Tends to have significant price volatility around earnings, particularly after the strong positive reaction to Q1 2026 results, indicating high sensitivity to financial performance.
Key Metrics to Watch
Competitive Position
Top Competitor
Sanofi (Fabrazyme), Takeda (Replagal)
Market Share Trend
Gaining market share, albeit from a small base, in the established Fabry disease market due to Elfabrio's recent approval and Chiesi's commercialization efforts.
Valuation vs Peers
Trading at a discount to established biotech peers on a P/E basis (10.9 vs. industry average often 20x+), likely due to its small market cap, single-product dependency, and recent history of unprofitability.
Competitive Advantages
- •Proprietary ProCellEx plant cell-based protein expression system, potentially offering production advantages and specific therapeutic benefits (e.g., reduced immunogenicity).
- •Strategic global partnership with Chiesi for commercialization, providing extensive reach and resources.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive PLX Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (Est. late July/early Aug 2026): Strong Elfabrio product revenue (excluding milestones) exceeding $20M, validating commercial ramp-up.
- •Update on Elfabrio global market penetration (Q3 2026): Chiesi reports market share gains of 2%+ in key European territories.
Medium-Term (6-18 months)
- •New Elfabrio regulatory submission/approval (H1 2027): Filing for new geographic market (e.g., Japan, South America) by Chiesi, opening a new revenue stream projected to add $10-15M annually.
- •Clinical development update on next-gen ProCellEx candidate (Q4 2027): Entry of a new rare disease candidate into Phase 1/2 clinical trials, leveraging the platform beyond Fabry disease.
Long-Term (18+ months)
- •Market share capture in Fabry disease (FY2028): If Elfabrio achieves 15%+ global market share, driving sustained annual product revenue above $100M.
- •ProCellEx platform validation beyond Elfabrio (FY2029): Successful Phase 2 readout for a second drug candidate, diversifying pipeline and validating platform's broader utility.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for PLX?
- ✓
Watch quarterly Elfabrio product revenue (excluding milestone payments) – crossing $20M/quarter signals successful commercial ramp-up and sustained profitability.
- ✓
Watch cash balance – consistently maintaining above $40M (from Q1 2026's $51.1M) confirms financial health and reduces funding risk.
Bull Case Analysis
Sign up free to see the bull case
Competing with PLX
See how Protalix Biotherapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Protalix Biotherapeutics Inc PLX | $161.5M | 8.2 | 10.5 | $76.4M | 20.1% | 27.8% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Protalix Biotherapeutics Inc Makes Money
Protalix Biotherapeutics is a pharmaceutical company that develops and commercializes recombinant therapeutic proteins for rare diseases, primarily using its proprietary ProCellEx plant cell-based protein expression system. The company primarily generates revenue through licensing fees, milestone payments, and a share of product sales from its lead drug, Elfabrio (pegunigalsidase alfa), which treats Fabry disease. It partners with larger pharmaceutical companies, such as Chiesi Global Rare Diseases, for the global commercialization and distribution of its approved products, enabling it to focus on drug development while leveraging a partner's extensive market reach.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Protalix Biotherapeutics Inc (PLX)?
As of June 11, 2026, Protalix Biotherapeutics Inc has a DVR Score of 8.2 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Protalix Biotherapeutics Inc?
Protalix Biotherapeutics Inc's market capitalization is approximately $161.5M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Protalix Biotherapeutics Inc use?
PLX is the ticker symbol for Protalix Biotherapeutics Inc. The company trades on the ASE.
What is the risk level for PLX stock?
Our analysis rates Protalix Biotherapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PLX?
Protalix Biotherapeutics Inc currently has a price-to-earnings (P/E) ratio of 10.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Protalix Biotherapeutics Inc's revenue growing?
Protalix Biotherapeutics Inc has reported revenue growth of 27.8%. The company is showing strong top-line momentum.
Is PLX stock profitable?
Protalix Biotherapeutics Inc has a profit margin of 20.1%. This indicates strong profitability.
How often is the PLX DVR analysis updated?
Our AI-powered analysis of Protalix Biotherapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 11, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PLX (Protalix Biotherapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.